Asthma is a common chronic airway disease that affects children and adults. Environmental factors and a rapidly changing lifestyle have increased the incidence and prevalence of asthma in China. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair / Seretide, AstraZeneca’s Symbicort), oral drugs (montelukast), and biologics (Roche / Novartis’s Xolair). However, the market is evolving as generic alternatives to inhaled blockbuster agents continue to launch. Novel targeted therapies—benralizumab (AstraZeneca’s Fasenra) and mepolizumab (GSK’s Nucala)—are also in late-phase development in China for asthma. The launch and uptake of these agents will lead to significant growth of China’s asthma therapy market over 2021-2031. In addition, ongoing reforms in China’s regulatory and access and reimbursement landscape will increasingly encourage multinational companies to enter the market.
- How large is China’s drug-treatable asthma population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s asthma market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the asthma pipeline in China? What sales could they secure in asthma? What are interviewed experts’ opinions of these therapies?
- What are the key drivers of and constraints in China’s asthma therapy market, and how will the market evolve over the forecast period?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 25 pulmonologists and 25 PCPs.
Diagnosed prevalence of asthma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
10-year, annualized, drug-level sales, and patient share of key asthma therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 6 drugs; Phase II: 3 drugs; coverage of Phase I products.
- Asthma - Geographic Focus: China - Asthma - China In-Depth (China)
- Asthma - China In-Depth (China)
Karan Verma, M.Sc.
Karan Verma, M.Sc., is a lead healthcare research and data analyst on the China In-Depth team at Clarivate. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide Chinese market-specific insights in various therapy areas, including CAR T-cell therapies, prostate cancer, hepatocellular carcinoma, multiple myeloma, non-Hodgkin’s lymphoma, migraine, type 2 diabetes, and multiple sclerosis. He has expertise in market forecasting, competitive intelligence, benchmarking, and brand performance analytics. He obtained his M.Sc. in biomedical engineering from the University of Warwick in Coventry, United Kingdom, and a B.E. in biomedical engineering from Maharshi Dayanand University in Haryana, India.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.